Neumora Therapeutics, Inc. Common Stock (NMRA) 10-Year Financial Performance & Capital Metrics

NMRA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Show more

Revenue $0
EBITDA -$263M -40.2%
Net Income -$244M -3.3%
EPS (Diluted) -1.53 -2.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -64.48% +97.0%
ROIC -159.97% -13.6%
Debt/Equity 0.01 -42.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 92 (top 8%)
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.11%

ROCE

10Y Avg-55.33%

5Y Avg-55.33%

3Y Avg-48.73%

Latest-69.5%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	668K	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	-668K	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	1%
Operating Expenses+	95.52M	237.32M	135.87M	187.53M	263.46M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	8.39M	24.55M	31.12M	44.81M	62.54M
SG&A % of Revenue	-	-	-	-	-
Research & Development	87.13M	212.78M	104.75M	142.72M	200.93M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-95.52M	-237.32M	-135.87M	-188.19M	-263.46M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-1.48%	0.43%	-0.39%	-0.4%
EBITDA+	-95.41M	-236.78M	-135.28M	-187.53M	-262.83M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-1.48%	0.43%	-0.39%	-0.4%
D&A (Non-Cash Add-back)	105K	538K	594K	668K	631K
EBIT	-95.52M	-237.32M	-135.87M	-188.19M	-263.46M
Net Interest Income+	0	0	4.56M	16.61M	19.93M
Interest Income	0	0	4.56M	16.61M	19.93M
Interest Expense	0	0	0	0	0
Other Income/Expense	-3.75M	11K	4.97M	-47.46M	19.86M
Pretax Income+	-99.27M	-237.31M	-130.9M	-235.66M	-243.61M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	268K	178K
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-99.27M	-237.31M	-130.9M	-235.93M	-243.79M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-1.39%	0.45%	-0.8%	-0.03%
Net Income (Continuing)	-99.27M	-237.31M	-130.9M	-235.93M	-243.79M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.65	-1.56	-0.86	-1.49	-1.53
EPS Growth %	-	-1.4%	0.45%	-0.73%	-0.03%
EPS (Basic)	-0.65	-1.56	-0.86	-1.49	-1.53
Diluted Shares Outstanding	151.95M	151.95M	151.95M	158.83M	159.38M
Basic Shares Outstanding	151.95M	151.95M	151.95M	158.83M	159.38M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	193.84M	415.6M	387.95M	478.28M	314.06M
Cash & Short-Term Investments	191.98M	409.25M	371.88M	453.98M	307.58M
Cash Only	191.98M	409.25M	240.94M	374.04M	142.15M
Short-Term Investments	0	0	130.94M	79.94M	165.43M
Accounts Receivable	148K	200K	919K	939K	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	125K	125K	50K	0	6.48M
Total Non-Current Assets+	4.11M	13.69M	38.28M	17.92M	2.92M
Property, Plant & Equipment	3.92M	4.04M	10.64M	6.86M	2.92M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	23.51M	9.85M	0
Other Non-Current Assets	183K	9.65M	4.13M	1.21M	0
Total Assets+	197.95M	429.3M	426.23M	496.19M	316.97M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	1.17%	-0.01%	0.16%	-0.36%
Total Current Liabilities+	9.37M	23.28M	23.7M	25.11M	29.89M
Accounts Payable	2.4M	1.64M	7.15M	337K	3.31M
Days Payables Outstanding	-	-	-	184.14	-
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	4.13M	8.13M	10.04M	10.15M	10.11M
Current Ratio	20.69x	17.85x	16.37x	19.05x	10.51x
Quick Ratio	20.69x	17.85x	16.37x	19.05x	10.51x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	282.96M	731.24M	849.39M	2.01M	22K
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	1.28M	996K	5.07M	1.85M	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	281.68M	730.24M	844.32M	155K	22K
Total Liabilities	292.33M	754.52M	873.08M	27.12M	29.91M
Total Debt+	2.04M	2.05M	8.44M	5.23M	1.85M
Net Debt	-189.93M	-407.19M	-232.5M	-368.81M	-140.29M
Debt / Equity	-	-	-	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-	-
Total Equity+	-94.38M	-325.22M	-446.85M	469.08M	287.06M
Equity Growth %	-	-2.45%	-0.37%	2.05%	-0.39%
Book Value per Share	-0.62	-2.14	-2.94	2.95	1.80
Total Shareholders' Equity	-94.38M	-325.22M	-446.85M	469.08M	287.06M
Common Stock	13K	3K	3K	16K	16K
Retained Earnings	-99.29M	-336.61M	-467.51M	-703.43M	-947.22M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	-774K	-76K	62K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-26.76M	-75.42M	-114.9M	-163.28M	-182.94M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-1.82%	-0.52%	-0.42%	-0.12%
Net Income	-99.27M	-237.31M	-130.9M	-235.93M	-243.79M
Depreciation & Amortization	105K	538K	594K	668K	0
Stock-Based Compensation	1.68M	4.27M	8.3M	17.24M	39.99M
Deferred Taxes	3.08M	-53K	0	0	0
Other Non-Cash Items	70.77M	158.09M	14.06M	63.64M	-1.77M
Working Capital Changes	-3.12M	-961K	-6.95M	-8.9M	22.64M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	-4.67M	-759K	-1.25M	-581K	2.87M
Cash from Investing+	-11.24M	-817K	-168.01M	64.39M	-70.56M
Capital Expenditures	-1.3M	-817K	-511K	-117K	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	-9.94M	0	-13M	-4.59M	0
Cash from Financing+	230.1M	293.51M	115.74M	231.94M	21.6M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	1.37M	3.53M	-948K	7.91M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-28.06M	-76.24M	-115.41M	-163.4M	-182.94M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-1.72%	-0.51%	-0.42%	-0.12%
FCF per Share	-0.18	-0.50	-0.76	-1.03	-1.15
FCF Conversion (FCF/Net Income)	0.27x	0.32x	0.88x	0.69x	0.75x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-2122.96%	-64.48%
Return on Invested Capital (ROIC)	-	-	-	-140.77%	-159.97%
Debt / Equity	-	-	-	0.01x	0.01x
FCF Conversion	0.27x	0.32x	0.88x	0.69x	0.75x

Frequently Asked Questions

Growth & Financials

Neumora Therapeutics, Inc. Common Stock (NMRA) grew revenue by 0.0% over the past year. Growth has been modest.

Neumora Therapeutics, Inc. Common Stock (NMRA) reported a net loss of $236.3M for fiscal year 2024.

Dividend & Returns

Neumora Therapeutics, Inc. Common Stock (NMRA) has a return on equity (ROE) of -64.5%. Negative ROE indicates the company is unprofitable.

Neumora Therapeutics, Inc. Common Stock (NMRA) had negative free cash flow of $208.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener